Special Issue of AJMC on HCV: Access, Value, and Cost of Innovative Therapies

///Special Issue of AJMC on HCV: Access, Value, and Cost of Innovative Therapies

Special Issue of AJMC on HCV: Access, Value, and Cost of Innovative Therapies

2017-07-18T22:08:06+00:00 May 3rd, 2016|Research|

In a special issue of The American Journal of Managed Care (AJMC) on the Hepatitis C virus, released May 2016, IVI authors take up multiple key issues at the intersection of access, cost, and value from recent innovations in HCV treatment in four separate articles:

  • “Does Patient Cost Sharing for HCV Drug Make Sense?” authored by Darius Lakdawalla, Mark Linthicum, and Jacquelyn Vanderpuye-Orgle.
  • “Value of Expanding HCV Screening and Treatment Policies in the United States,” authored by Mark Linthicum, Darius Lakdawalla, and others.
  • “The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients,” with authors including Anupam B. Jena, Darius Lakdawalla, and Tomas Philipson.
  • “Costs and Spillover Effects of Private Insurers’ Coverage of Hepatitis C Treatment,” featuring Mark Linthicum, Darius Lakdawalla, and others.

In association with this special issue, AMJC and the National Viral Hepatitis Roundtable also held a congressional briefing in Washington DC to discuss policy challenges highlighted by the research. To view a video of the briefing, which includes presentations by Lakdawalla and Jena.

Source: American Journal of Managed Care